Version 1
: Received: 30 December 2023 / Approved: 3 January 2024 / Online: 3 January 2024 (08:47:28 CET)
How to cite:
Stancioiu, F.; Dumitrescu, R.; Bogdan, R.; Ivanescu, B. Autologous Cord Blood vs Individualized Supplements in Autistic Spectrum Disease – Results of the CORDUS Study. Preprints2024, 2024010134. https://doi.org/10.20944/preprints202401.0134.v1
Stancioiu, F.; Dumitrescu, R.; Bogdan, R.; Ivanescu, B. Autologous Cord Blood vs Individualized Supplements in Autistic Spectrum Disease – Results of the CORDUS Study. Preprints 2024, 2024010134. https://doi.org/10.20944/preprints202401.0134.v1
Stancioiu, F.; Dumitrescu, R.; Bogdan, R.; Ivanescu, B. Autologous Cord Blood vs Individualized Supplements in Autistic Spectrum Disease – Results of the CORDUS Study. Preprints2024, 2024010134. https://doi.org/10.20944/preprints202401.0134.v1
APA Style
Stancioiu, F., Dumitrescu, R., Bogdan, R., & Ivanescu, B. (2024). Autologous Cord Blood vs Individualized Supplements in Autistic Spectrum Disease – Results of the CORDUS Study. Preprints. https://doi.org/10.20944/preprints202401.0134.v1
Chicago/Turabian Style
Stancioiu, F., Raluca Bogdan and Bogdan Ivanescu. 2024 "Autologous Cord Blood vs Individualized Supplements in Autistic Spectrum Disease – Results of the CORDUS Study" Preprints. https://doi.org/10.20944/preprints202401.0134.v1
Abstract
Cellular therapies have started an important new therapeutic direction for Autistic Spectrum Disease (ASD), and the ample diversity of ASD pathophysiology and the different types of cell therapies need an equally ample effort for studying the applicable ASD causes and the specific benefits of cell therapies via clinical studies.CORDUS Clinical Study is a crossover study in which autologous cord blood was administered intravenously to 56 patients between January 2019 and July 2023, and has compared its efficacy versus an individualized combination of supplements; both treatments were administered in a different sequence to all participants. Treatment efficacy was evaluated pre- and post- treatments by an independent psychotherapist with ATEC, Q-CHAT and a 16-item comparative table score, after interviews with the children’s parents and therapists.Cord blood was beneficial in the group of 3–7-year-old children (n=28; 3 out of 4 children – 78.57% - improved scores), but was much less effective in kids older than 8 years or with body weight of more than 35 kg (n=28; 1 out of 10 children improved scores). Individualized supplements were more efficacious than cord blood in 5 cases out of 28, while in 23 kids cord blood brought more improvement than supplements; 6 kids registered minor or no improvement. Statistically significant improvements were seen after cord blood infusion on areas such as verbalization and social interaction, but not on irritability or aggressive behavior; also ample individual differences were noted. No serious adverse reactions were noted during and after cord blood or supplement administration.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
